Risk management is the key to achieving our investment objectives, and we manage our risk, in part, through portfolio diversification. Our portfolio is segmented by business sectors and sub-sectors, stage of growth, geography and risk profile. Our lending decisions take into consideration the unique challenges and opportunities facing each sector, and the changing windows of investment opportunity in the private and public equity markets.

Our clients focus on a range of therapeutic and research endeavors, including the central nervous system, oncology, inflammation, renal and cardiovascular diseases, gastrointestinal diseases, bacterial, viral and fungal infections, neoplastic diseases, autoimmune disorders and endocrine disorders. We lend to companies in the agricultural biotechnology sector researching microbial crop protectants, herbicides and fungicides, as well as plant genetics and output traits.